COPENHAGEN - Evaxion A/S (NASDAQ:EVAX) announced Thursday that MSD (tradename of Merck & Co., Inc.) has exercised its option to license Evaxion’s preclinical vaccine candidate EVX-B3 for a cash ...

MSD is reported to have been negotiating with Swiss biotech MoonLake Immunotherapeutics over a takeover deal – estimated to be worth more than $3 billion – according to media reports. The Financial ...

MSD has said it will cut $3 billion off its annual costs by the end of 2027 as it prepares for the end of patent protection for blockbuster cancer drug Keytruda the following year. The plan was ...

(Reuters) -Alliance Laundry is targeting a valuation of up to $4.34 billion in its U.S. initial public offering, the commercial laundry equipment maker said on Monday, as the frenzy around first-time ...

Heidelberg Materials (ETR:HEI) has had a rough month with its share price down 3.2%. However, a closer look at its sound financials might cause you to think again. Given that fundamentals usually ...

PARKLAND, Fla. — Parkland’s Marjory Stoneman Douglas High School was “placed on secure status as a precautionary measure after law enforcement received a tip about a possible weapon on campus” on ...

HEICO Corporation (NYSE:HEI.A) is one of the Best Performing Long Term Stocks According to Analysts. HEICO Corporation (NYSE:HEI.A) topped revenue and EPS estimates in FQ3 2025 with revenue of $1.15 ...

Merck (MSD) has received approval from the US Food and Drug Administration (FDA) for the subcutaneous format of its best-selling oncology asset, Keytruda. Image credit: U.P.SD via ShutterStock.com.